Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?

Combination of Approved Drug in COPD

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01010178

Enrollment

Registered

2009-11-09

Start date

2008-02-29

Completion date

2009-07-31

Last updated

2009-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPD, Macrolid, reversibility, Theophylline, Corticosteroids, symptoms PFT

Brief summary

Critical combination of various approved drugs in management for patients suffering with COPD.

Interventions

DRUGMacrolid, Theophylline, Inhaler Corticosteroids

we have no permission to include them in detail because of privacy policy of mentioned journal for publication

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

22 Years to 86 Years

Healthy volunteers

Inclusion criteria

* current or past smoker COPD

Exclusion criteria

* history of significant occupational or other environmental exposures or a connective tissue disease

Design outcomes

Primary

Measure	Time frame
15% increasing in forced expiratory volume in 1 second	6 months

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026